Cohance Lifesciences Limited — Updates, 12-08-2025: Press Release

Cohance Lifesciences is investing ₹23 Cr in a new cGMP oligonucleotide facility in Hyderabad. This strategic move significantly boosts its integrated oligonucleotide platform, enabling scale-up from R&D to commercial manufacturing with an annual GMP capacity of up to 700 kg. This complements a previous $10M US expansion, solidifying Cohance's position as a key partner for global pharma innovators in high-growth modalities like next-generation therapeutics. The facility is designed to meet stringent requirements, with customer engagements already underway.